AKAO 2018 Proxy Statement

11 by Galenica AG. Dr. Hillan holds an M.B. Ch.B. (Bachelor of Medicine and Surgery) degree from the Faculty of Medicine at the University of Glasgow, U.K. Dr. Hillan is a Fellow of the Royal College of Surgeons, and a Fellow of the Royal College of Pathologists. Dr. Hillan has authored dozens of scientific publications and is a named inventor on almost 50 issued patents. We believe that Dr. Hillan’s detailed knowledge of our company and his extensive background in the biotechnology industry, including his roles at Genentech, provide a critical contribution to our board of directors. Gregory Stea . Mr. Stea has served on our board of directors since June 2015. From September 2016 to January 2018, Mr. Stea held a consulting role to assist La Jolla Pharmaceutical Company in preparing for the commercialization of their first drug Angiotensin II. Prior to this, Mr. Stea retired from Cubist Pharmaceuticals having served as Senior Vice President, Commercial Operations, from 2009 to February 2015 where he led the growth of Cubicin, an acute care antibiotic, to unprecedented revenues. Most recently he led the launches of two additional acute care products prior to the Cubist acquisition by Merck. Mr. Stea was also a member of the Cubist Business Operating team responsible for corporate strategy, execution of the annual company plan and talent development. Prior to this, Mr. Stea served as Cubist’s Vice President, Sales and Marketing, from 2007 to 2009. Having joined Cubist as an original member of the commercial organization, Mr. Stea served as Head of Sales from 2002 to 2007. Mr. Stea was also an early employee at Amgen where he held leadership roles, including VP of Sales, from 1988 to 1997. He was instrumental in the launch and grown of Amgen’s first two products. Mr. Stea holds a bachelor’s degree in business administration from Temple University and completed the University of Michigan’s executive program as well as Harvard Business School’s program in leadership and strategy in pharmaceuticals and biotechnology. Mr. Stea brings to our board of directors extensive expertise in marketing and sales in the biotechnology and biopharmaceutical industries. Directors Continuing in Office Until the 2020 Annual Meeting of Stockholders John C. Doyle . Mr. Doyle has served on our board of directors since November 2012. Mr. Doyle has been with Castlight Health, Inc., a healthcare technology company (“Castlight”) since November 2012, where he currently serves as Chief Executive Officer and board member and previously served as President, Chief Operating Officer and Chief Financial Officer. Mr. Doyle served as Achaogen’s Chief Operating Officer from August 2009 to November 2009 and from February 2011 to November 2012, and as its Chief Financial Officer from November 2009 to February 2011. Mr. Doyle is a member of the 2012 class of Henry Crown Fellows at the Aspen Institute. He holds a B.S. in Business Administration from California Polytechnic State University, San Luis Obispo and an M.B.A. from the University of California, Berkeley. In addition to his historical perspective on Achaogen, Mr. Doyle brings to our board of directors his deep experience in operational and strategic planning, as well as general executive and leadership expertise, in the pharmaceuticals industry. Kent E. Lieginger, Pharm.D. Dr. Lieginger has served on our board of directors since March 2015. Dr. Lieginger served as Senior Vice President, Managed Care and Customer Operations at Genentech from 2004 to July 2014 and as Director of the Genentech Foundation from 2010 to 2012. He originally joined Genentech as Vice President, Managed Care and Customer Operations in 2004 and served as a member of Genentech’s Commercial Leadership Committee. Prior to joining Genentech, Dr. Lieginger was Vice President, National Insurer and Employer Segment (Managed Markets Division) at GlaxoSmithKline plc, a pharmaceutical company, where he also led teams in U.S. and global business development, finance, strategic contracting, manufacturing, marketing, and sales. He also served on the Board of Trustees at University of the Sciences in Philadelphia from August 2013 to July 2017. He completed his residency in clinical pharmacy at the University of California in San Francisco and served for four years as Assistant Clinical Professor of Medicine at the University of California, Davis School of Medicine. Dr. Lieginger brings to our board of directors his significant expertise in product development in the biotechnology industry.